Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print   

Wednesday 06 April, 2022

Tissue Regenix Group

Director/PDMR Shareholding

RNS Number : 5190H
Tissue Regenix Group PLC
06 April 2022
 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

 

Director/PDMR Shareholding

 

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces it has been notified that on 5 April 2022, Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, both individually purchased 1,785,000 Ordinary Shares of 0.1p each in the Company at a price of 0.44 pence per Ordinary Share, for a total consideration of £7,854 each.

 

Following the purchase, Mr Lee holds 5,262,200 Ordinary Shares in the Company representing 0.07% of the Company's issued share capital and Mr Cocke holds 5,692,000 Ordinary Shares in the Company representing 0.08% of the Company's issued share capital.

 

 

For more information:

 

Tissue Regenix Group plc

David Cocke, Chief Financial Officer

www.tissueregenix.com

Via Walbrook PR



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Nick Harland

Tel: +44(0)20 7710 7600 

Walbrook PR Ltd

Alice Woodings / Lianne Applegarth

Tel: +44 (0)20 7933 8780

  [email protected]

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Daniel Lee

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Tissue Regenix Group plc

b)

 

LEI

 

 

 213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.1p each



Identification code

GB00B5SGVL29

 


b)

 

Nature of the transaction

 

 

Purchase

c)

 

Price(s) and volume(s)

 

 

 

 


 

Price(s)

Volume(s)

 


 

0.44p

1,785,000

 


 

 

 

 

d)

 

Aggregated information




- Aggregated volume

1,785,000



- Price

£7,854



e)

 

Date of the transaction

 

 

5 April 2022

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM Market

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Cocke

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Tissue Regenix Group plc

b)

 

LEI

 

 

213800PNOD5UHQUFJI36

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 0.1p each



Identification code

GB00B5SGVL29

 


b)

 

Nature of the transaction

 

 

Purchase

c)

 

Price(s) and volume(s)

 

 

 

 


 

Price(s)

Volume(s)

 


 

0.44p

1,785,000

 


 

 

 

 

d)

 

Aggregated information




- Aggregated volume

1,785,000



- Price

£7,854



e)

 

Date of the transaction

 

 

5 April 2022

f)

 

Place of the transaction

 

 

London Stock Exchange, AIM Market

 

 


About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs such as in sports medicine, foot and ankle, and wound care.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBXGDSRUGDGDL

a d v e r t i s e m e n t